K+-channel inhibition reduces portal perfusion pressure in fibrotic rats and fibrosis associated characteristics of hepatic stellate cells

Inhibition of vascular calcification by block of intermediate conductance calcium-activated potassium channels with TRAM-34

(2014) Christian Freise et al.   PHARMACOLOGICAL RESEARCH

The K+ Channel KCa3.1 as a Novel Target for Idiopathic Pulmonary Fibrosis

(2014) Katy Morgan Roach et al.   PLoS One

Blockade of KCa3.1 Ameliorates Renal Fibrosis Through the TGF-β1/Smad Pathway in Diabetic Mice

(2013) Chunling Huang et al.   DIABETES

Evolving therapies for liver fibrosis

(2013) Detlef Schuppan et al.   JOURNAL OF CLINICAL INVESTIGATION

KCa3.1 mediates activation of fibroblasts in diabetic renal interstitial fibrosis

(2013) C. Huang et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

TRAM-34, a Putatively Selective Blocker of Intermediate-Conductance, Calcium-Activated Potassium Channels, Inhibits Cytochrome P450 Activity

(2013) Jay J. Agarwal et al.   PLoS One

Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis

(2010) Eleonora Patsenker et al.   JOURNAL OF HEPATOLOGY

Large-conductance calcium-activated potassium channels modulate vascular tone in experimental cirrhosis

(2010) Aina Rodríguez-Vilarrupla et al.   LIVER INTERNATIONAL

Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels

(2009) I. Grgic et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hepatic fibrosis—Overview

(2008) Scott L. Friedman   TOXICOLOGY